Advertisement
U.S. markets closed

Aptose Biosciences Inc. (APTO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.8600+0.0800 (+4.49%)
At close: 04:00PM EST
1.8600 0.00 (0.00%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close1.7800
Open1.8100
Bid1.8200 x 1300
Ask1.8400 x 900
Day's Range1.7800 - 1.8600
52 Week Range0.3600 - 6.6000
Volume61,636
Avg. Volume89,619
Market Cap29.215M
Beta (5Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-7.7200
Earnings DateMar 21, 2024 - Mar 25, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for APTO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aptose Biosciences, Inc.
    Analyst Report: Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more